Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | PKM | P14618 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729528 | 1.00 | CES2 (0.50) | CES2CES1KMT2ATDP1POLB | |
| SCHEMBL9782343 | 1.00 | CES2 (0.50) | CES2CES1KMT2ATDP1POLB | |
| SCHEMBL13983961 | 0.85 | CES2 (0.52) | CES2CES1KMT2ATDP1POLB | |
| SCHEMBL4609969 | 0.85 | CES2 (0.52) | CES2CES1KMT2ATDP1POLB | |
| SCHEMBL11457463 | 0.85 | CES2 (0.52) | CES2CES1KMT2ATDP1POLB | |
| SCHEMBL2812477 | 0.85 | CES2 (0.52) | CES2CES1KMT2ATDP1POLB | |
| SCHEMBL17426488 | 0.83 | CES2 (0.50) | CES2CES1KMT2ATDP1POLB | |
| SCHEMBL12180935 | 0.83 | CES2 (0.50) | CES2CES1KMT2ATDP1POLB | |
| SCHEMBL5217865 | 0.83 | CES2 (0.50) | CES2CES1KMT2ATDP1POLB | |
| SCHEMBL9634783 | 0.83 | CES2 (0.55) | CES2CES1KMT2ATDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041275-A1 | PRODRUGS | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
| US-5395931-A | 6-amido-1-methyl-2-(substituted-thio)carbapenems | MERCK & CO., INC. (US) | 1995-03-07 | — | — | US | disclosed |
| EP-0222022-B1 | PROCESS FOR PRODUCING BETA-LACTAM DERIVATIVES | Otsuka Kagaku Kabushiki Kaisha (JP) | 1992-09-23 | — | — | EP | disclosed |
| US-4210587-A | 7-Acylamino-3-[1-[2-(carboxymethylamino)ethyl]tetrazol-5-ylthio methyl]-3-cephem-4-carboxylic acids | SMITHKLINE CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
| US-4174323-A | BACTERICIDE, CEPHALOSPORIN INTERMEDIATES | SMITHKLINE CORPORATION (US) | 1979-11-13 | — | — | US | disclosed |
| US-4174324-A | 3-(Carboxymethyl)thio-1H-1,2,4-triazol-5-thione | SMITHKLINE CORPORATION (US) | 1979-11-13 | — | — | US | disclosed |
| US-4164447-A | TRANSFERS A CARBAMOYL GROUP TO 3-HYDROXYMETHYL CEPHALOSPORIN | GLAXO LABORATORIES LIMITED (GB) | 1979-08-14 | — | — | US | disclosed |
| EP-0000285-A1 | 7-Acylamino-3-((3-(carboxymethyl) thio-1 H-1,2,4-triazol-5-yl) thiomethyl)-3-cephem-4-carboxylic acid derivatives, processes for their preparation and compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-01-10 | — | — | EP | disclosed |
| EP-0000100-A1 | 7-Acylamino-3-(1-(2-sulfamoylaminoethyl)-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acids, a process for their preparation and compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1978-12-20 | — | — | EP | disclosed |
| US-4117124-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4117123-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4117125-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-3976546-A | HYDROLYSIS, ESTERASE | GLAXO LABORATORIES LIMITED (EN) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | CES2 228/4885CES1 292/4885KMT2A 3465/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | CES2 942/4885CES1 78/4885KMT2A 4375/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | CES2 228/4885CES1 292/4885KMT2A 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.